Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/31586
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJoshi, Omkar-
dc.contributor.authorRoy, Archna-
dc.contributor.authorJanodia, Manthan-
dc.date.accessioned2015-06-04T05:05:11Z-
dc.date.available2015-06-04T05:05:11Z-
dc.date.issued2015-05-
dc.identifier.issn0975-1076 (Online); 0971-7544 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/31586-
dc.description147-154en_US
dc.description.abstractPharmaceutical products in Australia can win up to five years of Patent Term Extension (PTE). This article reviews Australian PTE Law and its relationship with regulatory pathway for approving medicinal products. The article describes recent PTE cases involving pharmaceutical products and analyses how effective these PTE provisions are in Australia. Finally, it compares PTE provisions in Australia with European SPC (Supplementary Protection Certificate) and USA PTE Provisions. en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceJIPR Vol.20(3) [May 2015]en_US
dc.subjectTGAen_US
dc.subjectARTGen_US
dc.subjectSection 223en_US
dc.subjectEscitalopramen_US
dc.subjectLohmanen_US
dc.titlePTE Provisions Relating to Pharmaceutical Products in Australia in Comparison with European SPC and USA PTEen_US
dc.typeArticleen_US
Appears in Collections:JIPR Vol.20(3) [May 2015]

Files in This Item:
File Description SizeFormat 
JIPR 20(3) 147-154.pdf100.85 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.